Pronóstico del mercado terapéutico de enfermedades infecciosas de América del Norte hasta 2030 – Análisis regional – por clase de medicamento (antiviral, antibacteriano, antifúngico y otros), indicación (VIH, hepatitis, tuberculosis, influenza, VPH y otros), ruta De Administración (Oral, Parenteral, Tópica y Otros) y Canal de Distribución (Farmacias Hospitalarias, Farmacias Minoristas y Otros)
La creciente prevalencia de enfermedades infecciosas impulsa el mercado terapéutico de enfermedades infecciosas en América del Norte
Las enfermedades infecciosas son causadas por virus, parásitos, bacterias, hongos, productos tóxicos y otros agentes infecciosos. El VIH es un importante problema de salud pública en todo el mundo. Según el Programa Conjunto de las Naciones Unidas sobre el VIH/SIDA (ONUSIDA), en 2020, ~ 37,7 millones de personas tenían VIH. De ellos, 36 millones eran adultos y 1,7 millones eran niños de 0 a 14 años. Además, más de la mitad (53%) eran niñas y mujeres. Además, en 2020 se notificaron 1,5 millones de nuevos casos de VIH en todo el mundo. De manera similar, la hepatitis es una infección del hígado causada por una infección viral. Los principales tipos de virus de la hepatitis son A, B, C, D y E. Según la Organización Mundial de la Salud (OMS), a nivel mundial, ~ 58 millones de personas padecen infección crónica por el virus de la hepatitis C, y cada año, ~ 1,5 millones. se producen nuevas infecciones.
Según la OMS, la tuberculosis (TB) es la decimotercera causa de muerte a nivel mundial y la segunda enfermedad infecciosa después de COVID-19. En 2020, la tuberculosis causó 1,5 millones de muertes (incluidas 214.000 personas afectadas por el VIH). Además, 10 millones de personas padecían tuberculosis en todo el mundo en 2020, incluidos 1,1 millones de niños, 3,3 millones de mujeres y 5,6 millones de hombres. Además, las infecciones adquiridas en hospitales o las infecciones asociadas a la atención sanitaria (IAAS) tienen una alta tasa de morbilidad y mortalidad. Además, el gasto en el sistema sanitario es enorme cada año. Los Centros para el Control y la Prevención de Enfermedades (CDC) informaron que las HAI representan aproximadamente 1,7 millones de casos de infección y 99.000 muertes cada año en los hospitales estadounidenses. Por lo tanto, la creciente prevalencia de enfermedades infecciosas en todo el mundo impulsa el crecimiento del mercado terapéutico de enfermedades infecciosas.
Descripción general del mercado de terapias para enfermedades infecciosas en América del Norte
El mercado de terapias para enfermedades infecciosas en América del Norte está segmentado en EE. UU., Canadá y México. América del Norte representó la mayor parte del mercado mundial en 2022. Se prevé que la creciente adopción de avances tecnológicos y el aumento de las actividades de investigación y desarrollo aceleren el crecimiento del mercado terapéutico de enfermedades infecciosas. Además, las grandes empresas sanitarias y la creciente demanda de soluciones terapéuticas avanzadas para tratar enfermedades crónicas y virales están impulsando la expansión del mercado en esta región. Se prevé que la creciente demanda de agentes antivirales debido a la creciente adopción de terapias antivirales impulse el mercado en Estados Unidos. Las principales empresas farmacéuticas y biofarmacéuticas se centran en ampliar sus capacidades de fabricación de agentes antivirales. Por ejemplo, Gilead Sciences, Inc., California, recibió la aprobación de la FDA para su antiviral en investigación, Remdesivir, para tratar la COVID-19 en mayo de 2020. Además, en abril de 2022, la Administración de Alimentos y Medicamentos de EE. UU. (FDA) aprobó un nuevo medicamento complementario. solicitud (sNDA) de Gilead Sciences para Veklury (remdesivir) para el tratamiento de pacientes pediátricos de más de 28 días, que pesen al menos 3 kg y estén hospitalizados para recibir tratamiento por COVID-19 o tengan una infección por COVID-19 de leve a moderada. En septiembre de 2021, la Administración Biden-Harris invirtió 2.100 millones de dólares a través de los Centros para el Control y la Prevención de Enfermedades (CDC) para mejorar las actividades de prevención y control de infecciones en los sectores de salud pública y atención sanitaria del país. Se prevé que estos factores impulsen el crecimiento del mercado terapéutico de enfermedades infecciosas de EE. UU. durante el período de pronóstico.
Ingresos del mercado de terapias para enfermedades infecciosas de América del Norte y pronóstico hasta 2030 (millones de dólares estadounidenses)
Segmentación del mercado de terapias para enfermedades infecciosas de América del Norte
Se clasifica el mercado de terapias para enfermedades infecciosas de América del Norte por clase de fármaco, indicación, vía de administración, canal de distribución y país.
Según la clase de fármaco, el mercado terapéutico de enfermedades infecciosas de América del Norte se segmenta en antivirales, antibacterianos, antifúngicos y otros. El segmento antiviral tuvo la mayor cuota de mercado en 2022.
En términos de indicación, el mercado terapéutico de enfermedades infecciosas de América del Norte está segmentado en VIH, hepatitis, tuberculosis, influenza, VPH y otros. El VIH tuvo la mayor participación de mercado en 2022.
Según la vía de administración, el mercado terapéutico de enfermedades infecciosas de América del Norte se segmenta en oral, parenteral, tópico y otros. El segmento oral tuvo la mayor participación de mercado en 2022.
En términos de canal de distribución, el mercado terapéutico de enfermedades infecciosas de América del Norte está segmentado en farmacias hospitalarias, farmacias minoristas y otros. Las farmacias hospitalarias tuvieron la mayor participación de mercado en 2022.
Por país, el mercado terapéutico de enfermedades infecciosas de América del Norte está segmentado en EE. UU., Canadá y México. Estados Unidos dominó la cuota de mercado de terapias para enfermedades infecciosas en América del Norte en 2022.
AbbVie Inc, Astellas Pharma Inc, Bayer AG, BioCryst Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc, Merck & Co Inc, Pfizer Inc y Shionogi & Co Ltd son algunas de las empresas líderes que operan en el mercado terapéutico de enfermedades infecciosas de América del Norte.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Infectious Disease Therapeutics Market - Key Market Dynamics
4.1 North America Infectious Disease Therapeutics Market - Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Infectious Disease
4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
4.3 Market Restraints
4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
4.4 Market Opportunities
4.4.1 Growing Opportunities in Developing Nations
4.4.2 Escalating Threat of Antibiotic Resistance
4.5 Future Trends
4.5.1 Rising Number of Product Approvals and Launches
4.6 Impact of Drivers and Restraints:
5. Infectious Disease Therapeutics Market - North America Market Analysis
5.1 North America Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
6. North America Infectious Disease Therapeutics Market Analysis - by Drug Class
6.1 Overview
6.2 Anti-Viral
6.2.1 Overview
6.2.2 Anti-viral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Anti-bacterial
6.3.1 Overview
6.3.2 Anti-bacterial: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Anti-fungal
6.4.1 Overview
6.4.2 Anti-fungal: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. North America Infectious Disease Therapeutics Market Analysis - by Indication
7.1 Overview
7.2 HIV
7.2.1 Overview
7.2.2 HIV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Hepatitis
7.3.1 Overview
7.3.2 Hepatitis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Tuberculosis
7.4.1 Overview
7.4.2 Tuberculosis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Influenza
7.5.1 Overview
7.5.2 Influenza: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.6 HPV
7.6.1 Overview
7.6.2 HPV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. North America Infectious Disease Therapeutics Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Topical
8.4.1 Overview
8.4.2 Topical: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. North America Infectious Disease Therapeutics Market Analysis - by Distribution Channel
9.1 Overview
9.2 Hospital Pharmacies
9.2.1 Overview
9.2.2 Hospital Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10. North America Infectious Disease Therapeutics Market - Country Analysis
10.1 North America Infectious Disease Therapeutics Market Overview
10.1.1 North America Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.1 North America Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.2 United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.3 United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 United States: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.3.2 United States: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.3.3 United States: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.3.4 United States: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.4 Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Overview
10.1.1.5 Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 Canada: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.5.2 Canada: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.5.3 Canada: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.5.4 Canada: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.6 Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Overview
10.1.1.7 Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.7.1 Mexico: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.7.2 Mexico: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.7.3 Mexico: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.7.4 Mexico: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
11. Infectious Disease Therapeutics Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Infectious Disease Therapeutics Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Pfizer Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Gilead Sciences Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 F. Hoffmann-La Roche Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Shionogi & Co Ltd
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Bayer AG
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 BioCryst Pharmaceuticals Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 GSK Plc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 AbbVie Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Merck & Co Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Astellas Pharma Inc
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
List of Tables
Table 1. North America Infectious Disease Therapeutics Market Segmentation
Table 2. Diseases and Funding
Table 3. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
Table 4. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
Table 5. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 6. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 7. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country
Table 8. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 9. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 10. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 11. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 12. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 13. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 14. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 15. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 16. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 17. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 18. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 19. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 20. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
Table 21. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market
List of Figures
Figure 1. North America Infectious Disease Therapeutics Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. North America Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
Figure 4. North America Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
Figure 5. Anti-viral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Anti-bacterial: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Anti-fungal: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. North America Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
Figure 10. HIV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Tuberculosis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Influenza: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. HPV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. North America Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
Figure 17. Oral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Parenteral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Topical: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. North America Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. North America Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. North America Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Growth Strategies in the Infectious Disease Therapeutics Market
1. AbbVie Inc
2. Astellas Pharma Inc
3. Bayer AG
4. BioCryst Pharmaceuticals Inc
5. F. Hoffmann-La Roche Ltd
6. Gilead Sciences Inc
7. GSK Plc
8. Merck & Co Inc
9. Pfizer Inc
10. Shionogi & Co Ltd
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America infectious disease therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America infectious disease therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America infectious disease therapeutics market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.